

DAFTAR PUSTAKA

1. Pophali PA, Patnaik MM. The Role of New Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia. *Cancer J*. 2016;22(1):40–50.
2. Oehler VG. First-generation vs second-generation tyrosine kinase inhibitors: which is best at diagnosis of chronic phase chronic myeloid leukemia? *Hematology*. 2020 Dec 4;2020(1):228–36.
3. Kennedy JA, Hobbs G. Tyrosine kinase inhibitors in the treatment of chronic phase CML: strategies for frontline decision-making. *Curr Hematol Malig Rep*. 2018 Jun;13(3):202–11.
4. Shoukier M, Kubiak M, Cortes J. Review of New-Generation Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia. *Curr Oncol Rep*. 2021 Jun 14;23(8):91.
5. Rajabto W, Reksodiputro AH, Rinaldi I, Tadjoeidin H, Priantono D, Angkasa YK. Chronic Myeloid Leukemia (CML) at National Referral Hospital in Indonesia. *Siriraj Medical Journal*. 2022 Aug;74(8):530–6.
6. Hehlmann R. Chronic Myeloid Leukemia in 2020. *Hemasphere*. 2020 Oct;4(5):e468.
7. Osman AE, Deininger MW. Chronic Myeloid Leukemia: Modern therapies, current challenges and future directions. *Blood Rev*. 2021 Sep;49:100825.
8. Sacha T. Imatinib in chronic myeloid leukemia: an overview. *Mediterr J Hematol Infect Dis*. 2014 Jan 2;6(1):e2014007
9. Blay JV, Mehren MV. Nilotinib: a novel, selective tyrosine kinase inhibitor. *Semin Oncol*. 2011 Apr;38(1):3-9
10. Ono T. Which Tyrosine Kinase Inhibitors Should Be Selected as the First-Line Treatment for Chronic Myelogenous Leukemia in Chronic Phase? *Cancers (Basel)*. 2021 Oct 12;13(20):5116.
11. Rinaldi I, Winston K. Chronic Myeloid Leukemia, from Pathophysiology to Treatment-Free Remission: A Narrative Literature Review. *J Blood Med*. 2023;14:261–77.
12. Walia A, Prasad V. Current CML guidelines overemphasize second generation TKIs: revisiting the paradigm. *Blood Cancer J*. 2023 Mar 15;13(1):1–3.
13. Sumantri AS, Oehadian A, Wijaya I, Vidyaniati P, Rahmaniati. Therapeutic responses of imatinib and nilotinib among CML pasients in Hasan Sadikin Hospital Bandung. *Indonesian Journal of Cancer*. 2018 Dec;12(2):88-94

14. Maroselli P, Fanciullino R, Colle J, Farnault L, Roche P *et al.* Body mass index affects imatinib exposure: real-world evidence from TDM with adaptive dosing. *Fundam Clin Pharmacol.* 2025 Jan 3;39(1):e13049
15. Dewi SL. Beberapa titik kritis kebijakan obat dalam system jaminan social. *Jurnal Kebijakan Kesehatan Indonesia.* 2014 Mar;3(1):1-2
16. Wardati Y, Maulana A. Analisa efektivitas biaya penggunaan Imatinib dan Nilotinib pada pasien leukemia myeloid kronis di suatu rumah sakit di Bandung. *Prosiding Seminar Nasional dan Diseminasi Senelitian Kesehatan.* 2018 Apr;1:186-90
17. Chapman J, Zhang Y. Histology, Hematopoiesis. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2025.
18. Nagel S. NKL-Code in Normal and Aberrant Hematopoiesis. *Cancers (Basel).* 2021 Apr 19;13(8):1961.
19. Kantarjian H, Cortes J, Jabbour E, O'Brien S. Chronic myeloid leukemia. In: *Molecular Hematology.* John Wiley & Sons, Ltd; 2019. p. 71–86.
20. Minciacchi VR, Kumar R, Krause DS. Chronic Myeloid Leukemia: A Model Disease of the Past, Present and Future. *Cells.* 2021 Jan 10;10(1):117.
21. Shallis RM, Wang R, Davidoff A, Ma X, Podoltsev NA, Zeidan AM. Epidemiology of the classical myeloproliferative neoplasms: The four corners of an expansive and complex map. *Blood Rev.* 2020 Jul;42:100706.
22. Rohrbacher M, Hasford J. Epidemiology and Etiology of Chronic Myeloid Leukemia. In: Wiernik PH, Dutcher JP, Gertz MA, editors. *Neoplastic Diseases of the Blood.* Cham: Springer International Publishing; 2018. p. 9–17.
23. Khalid R, Riasat S. Molecular pathogenesis and treatment strategies of Chronic Myeloid Leukemia (CML). *Sudan Journal of Medical Sciences.* 2023;18(4):525–38.
24. Cortes J, Pavlovsky C, Sauße S. Chronic myeloid leukaemia. *The Lancet.* 2021 Nov 20;398(10314):1914–26.
25. Eden RE, Coviello JM. Chronic Myelogenous Leukemia. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2025.
26. Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, *et al.* European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. *Leukemia.* 2020 Apr;34(4):966–84.

27. Atallah E, Mauro MJ, Hochhaus A, Boquimpani C, Minami Y, Maheshwari VK, et al. Matching-adjusted indirect comparison of asciminib versus other treatments in chronic-phase chronic myeloid leukemia after failure of two prior tyrosine kinase inhibitors. *J Cancer Res Clin Oncol*. 2023 Aug;149(9):6247–62.
28. Sato E, Iriyama N, Tokuhira M, Takaku T, Ishikawa M, Nakazato T, et al. The EUTOS long-term survival score predicts disease-specific mortality and molecular responses among patients with chronic myeloid leukemia in a practice-based cohort. *Cancer Med*. 2020 Dec;9(23):8931–9.
29. Yang X, Bai Y, Shi M, Zhang W, Niu J, Wu C, et al. Validation of the EUTOS Long-Term Survival Score in Chinese Chronic Myeloid Leukemia Patients Treated with Imatinib: A Multicenter Real-World Study. *Cancer Manag Res*. 2020;12:1293–301.
30. Hochhaus A, Saussele S, Rosti G, Mahon FX, Janssen JJWM, Hjorth-Hansen H, et al. Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Annals of Oncology* [Internet]. 2017 Jul 1 [cited 2025 Jun 6];28:iv41–51. Available from: <https://www.annalsofoncology.org/action/showFullText?pii=S0923753419421479>
31. Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring. *Am J Hematol* [Internet]. 2020 Jun 1 [cited 2025 Jun 6];95(6):691–709. Available from: <https://pubmed.ncbi.nlm.nih.gov/32239758/>
32. Cheng F, Yuan G, Li Q, Cui Z, Li W. Long-term outcomes of frontline imatinib therapy for chronic myeloid leukemia in China. *Front Oncol* [Internet]. 2023 [cited 2025 Jun 6];13:1172910. Available from: <https://pmc.ncbi.nlm.nih.gov/articles/PMC10185871/>
33. Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, et al. Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia. *New England Journal of Medicine*. 2017 Mar 9;376(10):917–27.
34. Belohlavkova P, Zackova D, Klamova H, Faber E, Karas M, Stejskal L, et al. Clinical efficacy and safety of first-line nilotinib or imatinib therapy in patients with chronic myeloid leukemia—Nationwide real life data. *Cancer Med* [Internet]. 2024 Sep 1 [cited 2025 Jun 6];13(17):e70158. Available from: [/doi/pdf/10.1002/cam4.70158](https://doi/pdf/10.1002/cam4.70158)
35. Song MK, Chung JS, Seol YM, et al. Mean cell volume can be an early predictor for the cytogenetic response of chronic myeloid leukemia patients

treated with imatinib. *Leuk Res.* 2009 Nov;33(11):1459–62. doi:10.1016/j.leukres.2009.04.017

36. Kloth JSL, Hamberg P, Mendelaar PAJ, Dulfer RR, van der Holt B, Eechoute K, et al. Macrocytosis as a potential parameter associated with survival after tyrosine kinase inhibitor treatment. *Eur J Cancer.* 2016;56:101–6.
37. Hughes TP, Ross DM. Moving treatment-free remission into mainstream clinical practice in CML. *Blood.* 2016;128(1):17–23.
38. Maroselli P, Fanciullino R, Colle J, Farnault L, Rocher P, Venton G, et al. Relationship of body mass index and plasma imatinib levels in CML patients and mitigation of clinical impact using PK-guided dosing strategy. *Journal of Clinical Oncology* [Internet]. 2024 Jun 1 [cited 2025 Jun 6];42(16_suppl):e18522–e18522. Available from: https://ascopubs.org/doi/pdf/10.1200/JCO.2024.42.16_suppl.e18522
39. Kawaguchi T, Hamada A, Hirayama C, Saito H, Kanaoka M, Maitani Y, et al. Relationship between an effective dose of imatinib, body surface area, and trough drug levels in patients with chronic myeloid leukemia. *Leukemia.* 2009;23(3):563–568.
40. Abdulla MAJ, Chandra P, Akiki S El, Aldapt MB, Sardar S, Chapra A, et al. Clinicopathological Variables and Outcome in Chronic Myeloid Leukemia Associated With BCR-ABL1 Transcript Type and Body Weight: An Outcome of European LeukemiaNet Project. *Cancer Control* [Internet]. 2021 [cited 2025 Jun 7];28:10732748211038428. Available from: <https://pmc.ncbi.nlm.nih.gov/articles/PMC8619745/>
41. Yu X, Zhao J, Xu J, Li L, Dong J, Yuan W, et al. Association of Dietary Profiles and Nutritional Status Among Patients with Hematologic Diseases: A Prospective Cohort Study. *Blood* [Internet]. 2024 Nov 5 [cited 2025 Jun 6];144(Supplement 1):7905. Available from: <https://ashpublications.org/blood/article/144/Supplement%201/7905/527964/Association-of-Dietary-Profiles-and-Nutritional>
42. Kantarjian HM, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. *N Engl J Med.* 2010;362(24):2260–70.
43. Hochhaus A, Saglio G, Hughes TP, Larson RA, Kim DW, Issaragrisil S, et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. *Leukemia* [Internet]. 2016 May 1 [cited 2025 Jun 6];30(5):1044–54. Available from: <https://pubmed.ncbi.nlm.nih.gov/26837842/>

44. Zhang BS, Chen YP, Lv JL, Yang Y. Comparison of the efficacy of nilotinib and imatinib in the treatment of chronic myeloid leukemia. *Journal of the College of Physicians and Surgeons Pakistan* [Internet]. 2019 Jul 1 [cited 2025 Jun 6];29(7):631–4. Available from: <https://pubmed.ncbi.nlm.nih.gov/31253213/>
45. Mauro MJ, Deininger MW. Management of drug toxicities in chronic myeloid leukemia. *Hematology Am Soc Hematol Educ Program*. 2019;2019(1):111–8.
46. Eşkazan AE, Kok CH, Yeung D, Dalal J, Tiribelli M. Editorial: Advances in the treatment of chronic myeloid leukemia. *Front Oncol* [Internet]. 2023 [cited 2025 Jun 6];13:1166588. Available from: <https://pmc.ncbi.nlm.nih.gov/articles/PMC10034855/>